Frequency Therapeutics, Inc. announced that on February 11, 2023, the Company's Board of Directors appointed Christopher Loose, Ph.D., as Interim Chief Executive Officer while David Lucchino, the Company's President and Chief Executive Officer, is on a temporary medical leave of absence after being hospitalized with bacterial meningitis. Mr. Lucchino is expected to make a full recovery. Dr. Loose will also continue to serve as the Company's Chief Scientific Officer.

The Company expects Mr. Lucchino will resume his position in full as Chief Executive Officer upon his return. Dr. Loose, age 42, co-founded the Company and has served as its Chief Scientific Officer since January 2016. Prior to founding the Company, Dr. Loose co-founded Semprus with Mr. Lucchino and Dr. Robert Langer and served as its Chief Technology Officer from June 2007 until its acquisition by Teleflex in June 2012.

At Semprus, he led the technology team in the development through regulatory clearance of medical products designed to reduce infection and clotting. Prior to Semprus, Dr. Loose worked as a chemical engineer at Merck Research Labs. In 2011, Dr. Loose was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation.

From 2014 to 2021, Dr. Loose served as an Associate Professor Adjunct of Urology at the Yale School of Medicine and Executive Director of Yale University's Center for Biomedical Innovation and Technology, and he continues to serve as a Lecturer in Yale School of Management. Dr. Loose holds a Ph.D. in Chemical Engineering from MIT and a BSE in Chemical Engineering summa cum laude from Princeton University.